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Although disease-causing prions are an extreme pathogenic aberration in protein behavior,
emerging evidence places them at the end of a broad spectrum of ordered protein aggregates
with diverse biological roles. This Select highlights recent findings on prions, including mutations
that push proteins with prion-like domains over the threshold to pathogenicity in degenerative dis-
orders, a vertebrate model of prion disease with the fastest known incubation time, and a system to
examine howcytoplasmic prions are transmitted between cells. A unique therapeutic perspective is
also offered by a recent study that suggests potential beneficial effects of prion-like amyloid fibrils
in neuroinflammatory diseases, such as multiple sclerosis.In the muscle of flies expressing human
hnRNPA2, wild-type protein is nuclear,
whereas the mutant form is found in
cytoplasmic inclusions. Image courtesy
of H. Kim.Living on the Edge of Bad Behavior
Proteins with prion-like domains are likely a rich source for the discovery of degen-
erative disease-causing mutations in humans. This is the take-home message of a
recent landmark study by Paul Taylor and colleagues (Kim et al., 2013), who, by
examining familial cases of multisystem proteinopathy and amyotrophic lateral
sclerosis, identify pathogenic mutations in prion-like domains of the RNA-binding
proteins hnRNPA2B1 and hnRNPA1. The prion-like domains correspond to ‘‘low-
complexity sequences,’’ a feature of many RNA-binding proteins, which underlies
their capacity to form ordered RNA granules. The authors show that both stress
granule formation and fibrillization are enhanced by the pathogenic mutations, and
in muscle biopsies from individuals with the mutations, cytoplasmic inclusions are
observed for the normally nuclear proteins. The mutations likely strengthen the
‘‘steric zipper’’ motif (wherein two layers of a b sheet interdigitate) pushing the
already aggregation-prone proteins down the road to more pathogenic prion-like
behavior. What are the steps from here? A first will be further investigation of
hnRNPA2B1 and hnRNPA1 in other familial and sporadic cases of proteinopathy
to get a sense of the frequency of their involvement. From there, the door is cast
wide open to examine the roles of other proteins that contain prion-like domains,
estimated at around 250 in humans, as potential instigators or collaborators in
degenerative disease.
Kim, H.J., et al. (2013). Nature 495, 467–473.NM prions in astrocytes (red). Image by
J. Hofmann.Aggregates Unbound
The prion precursor protein (PrP) in mammals is membrane anchored, and thus its
mode of transmission from cell to cell may differ from that of cytosolic aggregates,
such as the amyloids that are observed in numerous neurodegenerative diseases.
To examine the life cycle of cytosolic aggregates in mammalian cells, Hofmann
et al. (2013) establish coculture models that take advantage of a well-studied cyto-
solic yeast prion, the N-terminal and middle (NM) domain of Sup35. Growing cells
with NM-hemagglutinin-tagged aggregates with cells expressing soluble NM-green
fluorescent protein leads to the efficient induction of aggregate formation in the latter.
This effect is shown to depend on cell-to-cell contact and is observed in permanent
cell lines, cultured astrocytes, granule cell neurons, and hippocampal slices, suggest-
ing that the transmission mechanism is cell type independent. How then is the prion
transmitted? It appears to be direct exchange of aggregates between donor and
recipient cells, and although the exact mode of transfer awaits further characteriza-
tion, the authors propose the interesting possibility that aggregates might cross via
filopodial bridges. If so, in what circumstances, in addition to the transfer of aggre-
gates, do neighboring cells directly connect their cytoplasms, and what factors pro-
mote the interchange?
Hofmann, J.P., et al. (2013). PNAS. Published online March 18, 2013. http://dx.doi.org/10.1073/pnas.1217321110.Cell 153, April 25, 2013 ª2013 Elsevier Inc. 499
A bank vole from the breeding colony at the Istituto Superiore
di Sanita`. Image courtesy of M.A. Di Bari.Take It to the Bank (Vole)
Most prion diseases have long incubation periods; for example,
Creutzfeld-Jacob disease in humans often lies in wait for decades.
At the other end of the spectrum, Di Bari et al. (2013) report an
astonishingly short incubation period in an experimental model of
chronic wasting disease (CWD), an ailment that afflicts wild and
captive populations of deer, elk, and moose. They show that
CWD isolates from these species, when adapted to the bank vole
(Bv109ICWD), a small rodent native to Eurasia, have an incubation
time of 25–28 days culminating in a mean survival time of only
35 days. Besides this incredibly fast time course, which provides
a helpful tool for laboratory research on CWD pathogenesis, the
study raises a broader question about how host and prion factors
impact incubation periods for prion disease. What contributes to
the exceptionally short incubation period in bank voles? A clue is
provided by Watts et al. (2012), who generated mice that overex-press the bank vole prion protein precursor, BVPrP, including the same variant explored by Di Bari et al. with isoleucine at
codon 109. Thesemice spontaneously develop prion disease, and if brain isolates are then reinnoculated back into the BVPrP
transgenic mice, their survival time is only 35 days, similar to that seen for vole-adapted Bv109ICWD generated by Di Bari et al.
This contrasts with transgenic mice overexpressing the methionine codon 109 variant of vole PrP, which do not spontane-
ously exhibit prion disease, suggesting that isoleucine at that position is critical for the vole PrP’s enhanced pathogenic
propensity.
Di Bari, M.A., et al. (2013). PLoS Pathogens 9, e1003219.
Watts, J.C., et al. (2012) PNAS 109, 3498–3503.Histology of mouse experimental autoimmune encephalomy-
elitis. Image courtesy of L. Steinman.Putting a Hex on Inflammation
Proteins that are prone to aggregation are not just a cause of dis-
ease; they can have positive roles as well. Kurnellas et al. (2013)
demonstrate this using a variety of hexapeptides that form amyloid
fibrils, including segments of PrP, tau, and amyloid precursor pro-
tein. Mice injected with the hexapeptides exhibit reduced symp-
toms in experimental autoimmune encephalomyelitis (EAE), which
recapitulates features of multiple sclerosis in humans. How these
peptides have this effect in vivo is not yet clear, but in vitro exper-
iments indicate that the ability of the peptides to form fibrils corre-
lates with their capacity to act as chaperones in the inhibition of
insulin aggregation. Additionally, hexamers derived from tau (amino
acids 623–628) precipitate serum proteins, suggesting another
route by which the fibrils might alter the extracellular milieu to
impact inflammatory cytokine production. Regardless of the mech-
anism of action, which will undoubtedly be explored in future work,
the findings add a therapeutic perspective on the growing literature
on the native and beneficial functions of amyloids.
Kurnellas, M.P., et al. (2013). Sci. Transl. Med. 5, 179ra42.
Robert P. KrugerCell 153, April 25, 2013 ª2013 Elsevier Inc. 501
